![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The agreement aims to commercialise Akynzeo (combination of netupitant-palonosetron), for the treatment of chemotherapy-induced nausea and vomiting (CINV) in adult patients, in UK and Ireland.
Lead Product(s): Fosnetupitant Chloride,Palonosetron,Dexamethasone
Therapeutic Area: Gastroenterology Product Name: Akynzeo
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Helsinn Advanced Synthesis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 12, 2024